|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bacalbasa N, Balescu I, Dima S, Brasoveanu
V and Popescu I: Hematogenous splenic metastases as an independent
negative prognosis factor at the moment of primary cytoreduction in
advanced stage epithelial ovarian cancer-a single center
experience. Anticancer Res. 35:5649–5654. 2015.PubMed/NCBI
|
|
3
|
Rosell R, Lord RV, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Michailidou M, Brown HK, Lefley DV, Evans
A, Cross SS, Coleman RE, Brown NJ and Holen I: Microvascular
endothelial cell responses in vitro and in vivo: Modulation by
zoledronic acid and paclitaxel? J Vasc Res. 47:481–493.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Scholz HS, Tasdemir H, Hunlich T, Turnwald
W, Both A and Egger H: Multivisceral cytoreductive surgery in FIGO
stages IIIC and IV epithelial ovarian cancer: Results and 5-year
follow-up. Gynecol Oncol. 106:591–595. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vida A, Márton J, Mikó E and Bai P:
Metabolic roles of poly(ADP-ribose) polymerases. Semin Cell Dev
Bio. 65:135–143. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schreiber V, Dantzer F, Ame JC and de
Murcia G: Poly(ADP-ribose): Novel functions for an old molecule.
Nat Rev Mo Cell Bio. 7:517–528. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Walsh CS: Two decades beyond BRCA1/2:
Homologous recombination, hereditary cancer risk and a target for
ovarian cancer therapy. Gynecol Oncol. 137:343–350. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
He JX, Wang M, Huan XJ, Chen CH, Song SS,
Wang YQ, Liao XM, Tan C, He Q, Tong LJ, et al: Novel PARP1/2
inhibitor mefuparib hydrochloride elicits potent in vitro and in
vivo anticancer activity, characteristic of high tissue
distribution. Oncotarget. 8:4156–4168. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Phulwani NK and Kielian T: Poly
(ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation.
J Neurochem. 106:578–590. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kummar S, Chen A, Parchment RE, Kinders
RJ, Ji J, Tomaszewski JE and Doroshow JH: Advances in using PARP
inhibitors to treat cancer. BMC Med. 10(25)2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ricks TK, Chiu HJ, Ison G, Kim G, McKee
AE, Kluetz P and Pazdur R: Successes and challenges of PARP
inhibitors in cancer therapy. Front Oncol. 5(222)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Löser DA, Shibata A, Shibata AK, Woodbine
LJ, Jeggo PA and Chalmers AJ: Sensitization to radiation and
alkylating agents by inhibitors of poly(ADP-ribose) polymerase is
enhanced in cells deficient in DNA double-strand break repair. Mol
Cancer Ther. 9:1775–1787. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dedes KJ, Wilkerson PM, Wetterskog D,
Weigelt B, Ashworth A and Reis-Filho JS: Synthetic lethality of
PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell
Cycle. 10:1192–1199. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott CL, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
patients with platinum-sensitive relapsed serous ovarian cancer: A
preplanned retrospective analysis of outcomes by BRCA status in a
randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Parkes EE and Kennedy RD: Clinical
application of Poly(ADP-ribose) polymerase inhibitors in high-grade
serous ovarian cancer. Oncologist. 21:568–593. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Qin C, Zhang C, Zhu F, Xu F, Chen SY,
Zhang P, Li YH, Yang SY, Wei YQ, Tao L and Chen YZ: Therapeutic
target database update 2014: A resource for targeted therapeutics.
Nucleic Acids Res. 42 (Database Issue):D1118–D1123. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fong PC, Yap TA, Boss DS, Carden CP,
Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S,
Messiou C, et al: Poly(ADP)-ribose polymerase inhibition: Frequent
durable responses in BRCA carrier ovarian cancer correlating with
platinum-free interval. J Clin Oncol. 28:2512–2519. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lee JM, Hays JL, Annunziata CM, Noonan AM,
Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al:
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2
mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. 106(dju089)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Del Conte G, Sessa C, von Moos R, Viganò
L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A,
Cathomas R and Gianni L: Phase I study of olaparib in combination
with liposomal doxorubicin in patients with advanced solid tumours.
Br J Cancer. 111:651–659. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Konstantinopoulos PA, Ceccaldi R, Shapiro
GI and D'Andrea AD: Homologous recombination deficiency: Exploiting
the fundamental vulnerability of ovarian cancer. Cancer Discov.
5:1137–1154. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chou TC and Martin N: CompuSyn for Drug
Combinations: PC Software and User's Guide: A computer program for
quantitation of synergism and antagonism in drug combinations, and
the determination of IC50 and ED50 and
LD50 values. ComboSyn Inc., Paramus NJ, 2005.
|
|
23
|
Ashton JC: Drug combination studies and
their synergy quantification using the Chou-Talalay method-letter.
Cancer Res. 75(2400)2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Oza AM, Cibula D, Benzaquen AO, Poole C,
Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H,
et al: Olaparib combined with chemotherapy for recurrent
platinum-sensitive ovarian cancer: A randomised phase 2 trial.
Lancet Oncol. 16:87–97. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kamada K, Nakanishi T, Kitamoto M, Aikata
H, Kawakami Y, Ito K, Asahara T and Kajiyama G: Long-term prognosis
of patients undergoing transcatheter arterial chemoembolization for
unresectable hepatocellular carcinoma: Comparison of cisplatin
lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc
Interv Radiol. 12:847–854. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Garcia A and Singh H: Bevacizumab and
ovarian cancer. Ther Adv Med Oncol. 5:133–141. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Salminen A, Ojala J and Kaarniranta K:
Apoptosis and aging: Increased resistance to apoptosis enhances the
aging process. Cell Mol Life Sci. 68:1021–1031. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Minami D, Takigawa N, Takeda H, Takata M,
Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M and Kiura K:
Synergistic effect of olaparib with combination of cisplatin on
PTEN-deficient lung cancer cells. Mol Cancer Res. 11:140–148.
2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yasukawa M, Fujihara H, Fujimori H,
Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y
and Masutani M: Synergetic effects of PARP inhibitor AZD2281 and
cisplatin in oral squamous cell carcinoma in vitro and in vivo. Int
J Mol Sci. 17(272)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
de Groot JS, van Diest PJ, van Amersfoort
M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA,
de Bruin A, et al: Intraductal cisplatin treatment in a
BRCA-associated breast cancer mouse model attenuates tumor
development but leads to systemic tumors in aged female mice.
Oncotarget. 8:60750–60763. 2017.PubMed/NCBI View Article : Google Scholar
|
